NovoCure (NVCR) Competitors $16.21 -0.38 (-2.29%) Closing price 07/17/2025 04:00 PM EasternExtended Trading$16.27 +0.06 (+0.40%) As of 07/17/2025 07:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock NVCR vs. STVN, GKOS, BLCO, NARI, IRTC, SLNO, TMDX, INSP, NVST, and PRCTShould you be buying NovoCure stock or one of its competitors? The main competitors of NovoCure include Stevanato Group (STVN), Glaukos (GKOS), Bausch + Lomb (BLCO), Inari Medical (NARI), iRhythm Technologies (IRTC), Soleno Therapeutics (SLNO), TransMedics Group (TMDX), Inspire Medical Systems (INSP), Envista (NVST), and PROCEPT BioRobotics (PRCT). These companies are all part of the "medical equipment" industry. NovoCure vs. Its Competitors Stevanato Group Glaukos Bausch + Lomb Inari Medical iRhythm Technologies Soleno Therapeutics TransMedics Group Inspire Medical Systems Envista PROCEPT BioRobotics Stevanato Group (NYSE:STVN) and NovoCure (NASDAQ:NVCR) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, media sentiment, dividends, institutional ownership, analyst recommendations, valuation, earnings and risk. Does the media favor STVN or NVCR? In the previous week, Stevanato Group had 1 more articles in the media than NovoCure. MarketBeat recorded 3 mentions for Stevanato Group and 2 mentions for NovoCure. NovoCure's average media sentiment score of 0.86 beat Stevanato Group's score of 0.78 indicating that NovoCure is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Stevanato Group 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NovoCure 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend STVN or NVCR? NovoCure has a consensus target price of $32.43, suggesting a potential upside of 100.05%. Given NovoCure's higher probable upside, analysts plainly believe NovoCure is more favorable than Stevanato Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Stevanato Group 0 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.86NovoCure 0 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.71 Is STVN or NVCR more profitable? Stevanato Group has a net margin of 11.14% compared to NovoCure's net margin of -26.41%. Stevanato Group's return on equity of 10.00% beat NovoCure's return on equity.Company Net Margins Return on Equity Return on Assets Stevanato Group11.14% 10.00% 6.03% NovoCure -26.41%-45.46%-13.34% Which has more risk & volatility, STVN or NVCR? Stevanato Group has a beta of 0.55, indicating that its stock price is 45% less volatile than the S&P 500. Comparatively, NovoCure has a beta of 0.72, indicating that its stock price is 28% less volatile than the S&P 500. Do institutionals & insiders hold more shares of STVN or NVCR? 84.6% of NovoCure shares are owned by institutional investors. 0.7% of Stevanato Group shares are owned by company insiders. Comparatively, 5.5% of NovoCure shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has preferable valuation & earnings, STVN or NVCR? Stevanato Group has higher revenue and earnings than NovoCure. NovoCure is trading at a lower price-to-earnings ratio than Stevanato Group, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioStevanato Group€1.19B6.47€127.45M€0.5150.06NovoCure$605.22M2.99-$168.63M-$1.51-10.74 SummaryStevanato Group beats NovoCure on 11 of the 17 factors compared between the two stocks. Get NovoCure News Delivered to You Automatically Sign up to receive the latest news and ratings for NVCR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NVCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NVCR vs. The Competition Export to ExcelMetricNovoCureMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.85B$2.94B$5.57B$9.34BDividend YieldN/A2.45%3.80%4.06%P/E Ratio-10.7420.2928.1019.86Price / Sales2.99302.32441.4199.96Price / CashN/A43.1635.8457.94Price / Book4.877.838.265.67Net Income-$168.63M-$55.11M$3.24B$257.80M7 Day Performance-7.90%3.21%1.48%1.87%1 Month Performance-3.51%12.86%8.07%10.92%1 Year Performance-12.28%5.06%30.29%18.51% NovoCure Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NVCRNovoCure3.5446 of 5 stars$16.21-2.3%$32.43+100.1%-15.2%$1.85B$605.22M-10.741,488Upcoming EarningsSTVNStevanato Group1.1259 of 5 stars€24.23-1.5%N/A+17.8%€7.34B€1.19B47.515,521Positive NewsGKOSGlaukos4.352 of 5 stars$101.69-1.7%$134.67+32.4%-20.3%$5.81B$383.48M-42.91780Positive NewsBLCOBausch + Lomb1.7188 of 5 stars$13.83-0.4%$15.54+12.4%-15.4%$4.89B$4.83B-13.4313,500NARIInari Medical0.2577 of 5 stars$79.97flat$69.22-13.4%N/A$4.68B$493.63M-59.24800News CoverageIRTCiRhythm Technologies1.1468 of 5 stars$139.22-2.3%$138.60-0.4%+34.2%$4.44B$591.84M-44.342,000News CoverageAnalyst ForecastSLNOSoleno Therapeutics4.1974 of 5 stars$85.27-1.6%$107.10+25.6%+80.0%$4.30BN/A-18.4630TMDXTransMedics Group2.1056 of 5 stars$125.17-3.1%$127.33+1.7%-24.6%$4.23B$441.54M92.04210Analyst ForecastINSPInspire Medical Systems4.8727 of 5 stars$127.11-1.1%$211.91+66.7%-11.9%$3.75B$802.80M58.581,246Positive NewsAnalyst ForecastNVSTEnvista3.3833 of 5 stars$19.66-3.6%$20.23+2.9%+15.1%$3.33B$2.51B-3.0112,300News CoverageAnalyst RevisionPRCTPROCEPT BioRobotics2.2345 of 5 stars$56.97-1.6%$90.00+58.0%-17.3%$3.15B$224.50M-33.51430Analyst ForecastAnalyst Revision Related Companies and Tools Related Companies Stevanato Group Alternatives Glaukos Alternatives Bausch + Lomb Alternatives Inari Medical Alternatives iRhythm Technologies Alternatives Soleno Therapeutics Alternatives TransMedics Group Alternatives Inspire Medical Systems Alternatives Envista Alternatives PROCEPT BioRobotics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NVCR) was last updated on 7/18/2025 by MarketBeat.com Staff From Our PartnersElon Just Fired the IRS Agents Targeting Your SavingsElon Musk just fired 6,700 IRS agents — and exposed a war on your retirement. While D.C. scrambles to regai...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to tw...Crypto Swap Profits | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NovoCure Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share NovoCure With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
